Saban Sec
- Especialidad: Oncólogo clínico
- 13 años de experiencia
- Consultorio: Turquía, Estambul, Valued Med Hub Hospitals
- Representante de Médicos Especialistas de la Asociación Turca de Oncología Médica desde 2022. Miembro de la Cámara Médica de Estambul y de la Asociación Turca de Oncología Médica.
El Dr. Saban Sec es oncólogo médico con experiencia en hospitales de prestigio como el Hospital de Formación e Investigación Haseki, el Hospital Municipal Prof. Dr. Cemil Taşcıoğlu y el Hospital Bahçelievler Medikalpark. Actualmente representa a los médicos especialistas en la Asociación Turca de Oncología Médica. También es miembro de la Cámara Médica de Estambul y de la Asociación Turca de Oncología Médica.
El Dr. Sec trata cánceres de mama, pulmón, gastrointestinales, de próstata, urogenitales, de cabeza y cuello, así como sarcomas y tumores raros. Ha publicado numerosos artículos revisados por pares sobre pronóstico, resultados de tratamiento y tasas de supervivencia en cáncer. Su investigación incluye estudios con grandes grupos de pacientes, como 138 casos de cáncer gástrico metastásico HER2 positivo. El Dr. Sec se especializa en factores pronósticos y respuestas al tratamiento en distintos tipos de cáncer, y está comprometido con mejorar la atención oncológica.
Reseñas de paciente
Servicios médicos
- TEP/TC
- Biopsia
- Resonancia magnética cerebral
- TC (tomografía computarizada)
- Prueba de sangre de marcador tumoral
- Mamografía
- Resonancia magnética de un área
- Biopsia de pulmón
- Biopsia de mama
- Pruebas de función tiroidea (incluyendo T3, T4, TSH)
- Radiografía de pecho
- Biopsia de ovario
- Biopsia testicular
- Biopsia de tiroides
- Biopsia de páncreas
- Biopsia hepatica
- Biopsia de riñón
- RM cerebral con contraste (secuencia FLAIR)
- Biopsia cerebral
- Gastroscopia con biopsia
- Colonoscopia
- Angiografía
¿Qué tal su experiencia?
Formación académica
Experience
2012-2017 Haseki Training and Research Hospital Internal Medicine
2017 Kanuni Sultan Süleyman Training and Research Hospital Internal Medicine Specialist Dr.
2017-2021 Prof. Dr. Cemil Taşcıoğlu City Hospital Medical Oncology
2021-2022 Şanlıurfa Mehmet Akif İnan EAH Medical Oncology Specialist Dr.
2022 Bahçelievler Medikalpark Hospital
2022- Turkish Medical Oncology Association Specialist Physicians Representative
Professional Memberships
1) Istanbul Medical Chamber Member
2) Turkish Medical Oncology Association Member
Areas of Interest
1) Breast cancer,
2) Lung cancer
3) Gastrointestinal (colon, rectum, stomach, liver) cancers
4) Prostate cancer
5) Urogenital cancers
6) Head, neck cancers
7) Sarcoma treatments
8) Rare tumors
Research and publications.
Prognostic significance of high free T4 and low free T3 levels in non-thyroidal illness syndrome
…, D Kayaş, ET Canbaz, F Çetin, Ş Seçmeler… - European journal of …, 2018 - Elsevier
Background Non-thyroidal illness syndrome is characterized by decreased serum free T3 (FT3)
level and associates with long term mortality. Serum free T4 (FT4) may affect mortality …
Clinical and pathological characteristics of patients with high-risk breast cancer based on BRCA mutation profiles: a retrospective study
…, S Ay, A Sakin, B Ertürk, Ş Selections… - European journal of …, 2021 - ncbi.nlm.nih.gov
Objective: This study aimed to determine the differences in clinicopathological features of
Turkish patients with high-risk breast cancer based on the mutation status of two breast cancer …
Prognostic significance of mean platelet volume on local advanced non-small cell lung cancer managed with chemoradiotherapy
A Sakin, S Secmeler, S Arici, C Geredeli, N Yasar… - Scientific reports, 2019 - nature.com
Mean platelet volume (MPV), the most commonly used measure of platelet size, and is altered
in patients with malignancies. The aim of this study was to investigate the effect of MPV on …
The predictive role of metabolic tumor volume on no response to neoadjuvant chemotherapy in patients with breast cancer
…, C Geredeli, R Cekin, Ş Selections… - Journal of Oncology …, 2020 - journals.sagepub.com
Introduction To evaluate the predictive significance of pretreatment metabolic tumor volume
on pathologic response in patients who received neoadjuvant chemotherapy for breast …
Efficacy of trastuzumab and potential risk factors on survival in patients with HER2-positive metastatic gastric cancer
A Topcu, MM Atci, S Secmeler, M Besiroglu… - Future …, 2021 - Future Medicine
Aim: To evaluate the efficacy of trastuzumab and potential risk factors on survival in patients
with HER2-positive metastatic gastric cancer. Methods: We retrospectively included 138 …
The effects of diabetes and fasting plasma glucose on treatment of breast cancer with neoadjuvant chemotherapy
S Arici, C Geredeli, S Secmeler, R Cekin… - Current Problems in …, 2020 - Elsevier
Purpose To determine the effects of diabetes and fasting plasma glucose (FPG) level on the
pathologic response in patients with breast cancer who received neoadjuvant chemotherapy…
Major and minor salivary gland cancers: A multicenter retrospective study
…, NS Demirci, E Turkmen, T Şakalar, S Secmeler… - Head & …, 2023 - Wiley Online Library
Background Most of the studies on salivary gland cancers are limited for various reasons
such as being single‐center, small number of patients, including only major or minor SGCs, or …
Prognostic significance of primary tumor localization in stage II and III colon cancer
A Sakin, S Arici, S Secmeler, O Can… - World Journal of …, 2018 - ncbi.nlm.nih.gov
AIM To investigate the effects of tumor localization on disease free survival (DFS) and overall
survival (OS) in patients with stage II-III colon cancer. METHODS This retrospective study …
Factors affecting survival in neuroendocrine tumors: a 15-year single center experience
A Sakin, M Tambas, S Secmeler, O Can… - Asian Pacific Journal …, 2018 - ncbi.nlm.nih.gov
Background: Neuroendocrine tumors are a heterogeneous group of tumors that can originate
from all of the neuroendocrine cells in the body, mostly from the gastrointestinal tract. In…
The effect of body mass index on location of recurrence and survival in early-stage colorectal cancer
A Sakin, NS Samanci, S Secmeler, S Arici… - Journal of cancer …, 2020 - journals.lww.com
Materials and Methods: Patients that were followed up and treated in the Department of
Medical Oncology between 1999 and 2016 were retrospectively included in the study. patients…
Pretreatment Modified Glasgow Prognostic Score for Predicting Prognosis and Survival in Elderly Patients with Gastric Cancer Treated with Perioperative FLOT
E Melekoglu, E Bayram, S Secmeler, B Mete, B Sahin - Nutrients, 2023 - mdpi.com
Comparing the efficacy of regorafenib and 5-fluorouracil-based rechallenge chemotherapy in the third-line treatment of metastatic colorectal cancer
También le puede interesar
Pagos y Beneficios
Nuestros servicios no tienen costo
El pago se realiza directamente en la clínica o mediante transferencia a su cuenta bancaria oficial.
Algunas clínicas pueden requerir un depósito como parte de su política.
Pague cómodamente en cuotas flexibles.
Reciba recompensas por recomendar Bookimed a sus amigos.